## Abstract Survival from soft tissue tumors (STTs) has been improved because of the successful treatment. One of the late sequelae in STT survivors is the development of a second malignancy. The present study aimed at quantifying risks for second malignancies in patients with STTs, and risks for s
Second primary malignancies in patients with neuroendocrine tumors
✍ Scribed by Reina, J. J.; Serrano, R.; Codes, M.; Jiménez, E.; Bolaños, M.; Gonzalez, E.; Sevilla, I.
- Book ID
- 125378142
- Publisher
- Springer Milan
- Year
- 2014
- Tongue
- Spanish
- Weight
- 371 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1699-048X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Several studies report coexistent or subsequent primary tumors (SPT) among patients with malignant melanoma (MM), with the rate of incidence ranging from 1.5-20% depending on the sample size and the length and completeness of follow-up. ## METHODS. The authors followed a cohort of patients with c
## BACKGROUND. Patients with neuroendocrine gastrointestinal tumors usually present with inoperable metastatic disease and severe hormonal symptoms. Specific chemotherapy, interferon-␣ (IFN), and somatostatin analogs are established therapies for these patients, but all of them eventually fail. Hep
Background. Patients with cancer of the oral cavity and pharynx have been described to be particularly susceptible to the development of new cancers. Methods. Using data collected during 1973-1987 by nine population-based cancer registries in the United States, the authors evaluated risks of second